Topical PLA2 Inhibitor Formulations for Envenomation Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for envenomation, particularly from snake and arthropod bites, lack effective topical and transdermal solutions that can rapidly neutralize toxins and promote healing, often relying on systemic administration which may not be feasible in severe cases.
Innovation Solution
Compositions comprising PLA2 inhibitors, metalloprotease inhibitors, and antivenom, combined with absorption enhancement agents like DMSO and ethanol, formulated as topical creams, gels, or transdermal patches, which include additional agents such as local anesthetics and antibiotics to enhance penetration and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If systemic administration is used for treating envenomation, then the treatment can address severe cases, but it may not be feasible in severe cases and lacks rapid local action
Solution Approach 1:
The treatment is segmented into local topical/transdermal application at the bite site and systemic administration if needed. The topical formulation containing PLA2 inhibitors and metalloprotease inhibitors acts locally and rapidly at the site of envenomation, while systemic administration remains available for severe cases that require broader coverage.
Solution Approach 2:
Absorption enhancement agents (such as permeation promoters) serve as intermediaries to facilitate rapid transdermal delivery of the antivenom and enzyme inhibitors through the skin barrier, enabling quick local action without requiring invasive injection methods.
2Speed
If topical formulations are used for rapid toxin neutralization, then local action is improved, but penetration through skin barrier is limited
Solution Approach 1:
Absorption enhancement agents act as intermediaries that temporarily modify the skin barrier properties or facilitate drug transport across the stratum corneum, enabling reliable penetration of the topical formulation while maintaining rapid onset of action.
Solution Approach 2:
The formulation modifies physical-chemical parameters such as pH, solubility, and molecular size of the active ingredients to optimize their penetration through the skin barrier. The use of permeation promoters changes the local environment to enhance transdermal delivery efficiency.
3Reliability
If multiple active agents are combined in topical formulations, then treatment efficacy is improved, but formulation complexity increases
Solution Approach 1:
Multiple active agents (antivenom, PLA2 inhibitors, metalloprotease inhibitors, and absorption enhancement agents) are merged into a single topical or transdermal formulation. This combination approach delivers multiple therapeutic actions simultaneously through one application method, simplifying the treatment protocol while maintaining high efficacy.
Solution Approach 2:
The topical formulation is designed with multi-functionality, serving as both a toxin-neutralizing agent and a delivery system. The absorption enhancement agents simultaneously improve penetration of all active ingredients, making the formulation universally effective against various venom components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These formulations provide rapid absorption and toxin neutralization, reducing pain and slowing toxin spread, with DMSO demonstrating unexpected anti-metalloprotease activity, effectively treating envenomation even when applied remotely and potentially lifesaving in severe cases.
Implementation Method 1
The compositions according to the invention further comprise an absorption enhancement agent in effective amounts to assist the actives to penetrate the skin or mucosal membranes
Implementation Method 2
with DMSO demonstrating unexpected anti-metalloprotease activity
Implementation Method 3
the absorption enhancement agent is DMSO, an alcohol, glycol, vegetable fatty oil, or a derivative thereof
Data Source
AI summary
The present invention is directed to compositions comprising PLA2 inhibitors and optionally a metalloprotease inhibitor and/or an antivenom, antibody, antibody fragment or antibody derivative for topical, transdermal, buccal or sublingual administration, formulated especially as salves, creams, ointments, liniments, gels, films or tablets for topical, buccal or sublingual administration and patches and microneedle patches (which may include a massage or pressure pump to accelerate delivery and a band to secure the patch while providing sufficient pressure to inhibit the spread of toxin from a wound or envenoming site or the addition of an absorption accelerant incorporated into the device or added externally) for transdermal administration. The compositions according to the present invention may also be formulated with additional active agents such as antibiotics, steroids, analgesics, local anesthetics, additional actives and mixtures thereof to provide treatment for infections, wounds, injuries, inflammatory conditions and toxidromes, including those caused by bacteria, viruses, envenoming (venom-induced), especially snake and arthropod bites, as well as vesicant exposure and other wounds which traumatically arise from various causes at macro- and microscopic scales.